Join some of the top minds in risk minimisation as faculty and enjoy peer-to-peer interaction to discuss practical implementation and interpretation of Risk Minimisation Measures with this training course.

NEW OFFERING! Understanding Real World Evidence (RWE) and Observational studies using Real World Data (RWD) has become necessary not only for people working in pharmacovigilance but to everyone working in all stages of the lifecycle of medicines.

Explore how companies advance potential drug candidates through the earliest stages of research, from therapeutic target to readiness for clinical studies.

Learn the activities required to move a drug candidate from idea to the market, and how various functional areas are organized and contribute at each stage of development. Learn about the regulatory environment in which these activities occur.

Examine the activities associated with phase 1 development, with a focus on the drivers that impact the design of the first-in-human study.

Learn the factors that drive the design and conduct of phase 2 clinical trials, as well as the activities and functional areas that contribute to a successful phase 2 program.

Learn how organizations structure their efforts and utilize their resources to improve the odds of successful development in this six module program.

Review activities associated with the management of a marketed drug, as well as focus on how companies maximize the value of approved products through the lifecycle management process.